Related references
Note: Only part of the references are listed.Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Ignacio Garcia-Doval et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2016)
Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis
C. E. M. Griffiths et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Establishing an Academic-Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy
Christopher E. M. Griffiths et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Early clinical response as a predictor of efficacy in moderate to severe psoriasis patients treated with tofacitinib in a phase 2 study
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab
Anne Gedebjerg et al.
ACTA DERMATO-VENEREOLOGICA (2013)
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis
B. Zhu et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab
M. Talamonti et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U. Mrowietz et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2011)
Guidelines of care for the management of psoriasis and psoriatic arthritis
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Obesity and psoriasis: body weight and body mass index influence the response to biological treatment
L. Puig
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
The effect of weight on the efficacy of biologic therapy in patients with psoriasis
Lily Clark et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Share Paper
